Laigo Bio Closes €17M Seed Funding Round

Why It Matters

The funding validates Laigo’s novel SureTACs technology and positions it to challenge existing biologics in high‑need therapeutic areas, potentially reshaping oncology and immunology pipelines.

Key Takeaways

• €17M seed round completed, €5.5M second close.
• Biovance Capital leads with €4M new investment.
• SureTACs platform targets membrane proteins via bispecific antibodies.
• Funds accelerate oncology, autoimmune, graft rejection programs.
• Backed by Eurazeo, Angelini Ventures, and others.

Pulse Analysis

Laigo Bio’s recent €17 million seed round reflects a broader surge in early‑stage financing for precision‑medicine startups. Investors are increasingly drawn to platforms that can address “undruggable” targets, and Laigo’s SureTACs™ technology fits that narrative by leveraging bispecific antibodies to recruit E3 ligases for selective protein degradation. This model not only promises higher specificity than traditional monoclonal antibodies but also opens pathways to treat diseases where conventional small‑molecule inhibitors have failed.

The SureTACs platform distinguishes itself through its ability to engineer dual‑targeted therapeutics that degrade membrane proteins directly within the lysosome. By coupling an optimal E3 ligase to a disease‑associated antigen, the approach ensures rapid ubiquitination and clearance, reducing off‑target effects and resistance mechanisms common in kinase inhibitors. Such a mechanism is especially compelling for oncology, where membrane receptors drive tumor growth, and for autoimmune disorders, where precise modulation of immune checkpoints can restore tolerance.

Strategically, Laigo’s investor roster—spanning Biovance Capital, Kurma Partners, Eurazeo, and Angelini Ventures—provides not just capital but deep domain expertise and access to European clinical networks. This backing accelerates the transition from pre‑clinical validation to first‑in‑human trials, a critical inflection point for biotech valuation. As the company moves toward clinic, its success could catalyze further capital inflows into membrane‑protein degradation platforms, reshaping the competitive landscape for next‑generation biologics.

Deal Summary

Utrecht‑based biotech Laigo Bio announced the closing of its seed financing round, raising a total of €17 million, including a €5.5 million second close. New co‑lead investor Biovance Capital contributed €4 million, while co‑lead Kurma Partners added €1.5 million, alongside existing backers such as Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region and Cancer Research Horizons.